Nerisona (Diflucortolone Valerate)

Diflucortolone Valerate, the active ingredient in Nerisona, is a corticosteroid presented as a topical formulation for skin application. It is used to reduce inflammation and relieve symptoms in various inflammatory dermatoses, particularly in adult and pediatric patients requiring prescription‑strength therapy.

GNH USA supplies Nerisona as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Diflucortolone Valerate acts on inflammatory pathways of the skin, providing relief in several dermatologic conditions.

- Eczema: reduces inflammation, redness and itching associated with the condition. - Atopic dermatitis: controls flare‑ups and improves skin barrier function. - Psoriasis: diminishes plaque formation and scaling. - Contact dermatitis: alleviates irritation caused by external allergens. - Other inflammatory skin disorders: offers anti‑inflammatory benefit where topical glucocorticoids are indicated.

Topical application of diflucortolone valerate may be associated with local and, rarely, systemic adverse reactions.

Common Side Effects: - Burning or stinging sensation at the application site. - Mild itching or irritation. - Dryness or peeling of the treated skin.

Serious or Rare Side Effects: - Skin atrophy or thinning with prolonged use. - Development of telangiectasia (visible blood vessels). - Hypothalamic‑pituitary‑adrenal axis suppression leading to systemic glucocorticoid effects.

When using diflucortolone valerate, several precautions should be observed to minimize risk.

- Avoid use on infected or ulcerated skin: may worsen infection. - Limit duration of therapy: typically no longer than 2‑4 weeks. - Do not apply to broken skin or mucous membranes: increased systemic absorption. - Use the smallest effective amount: reduces risk of local side effects. - Pregnancy and lactation: safety not established, use only if benefit outweighs risk. - Store at room temperature: keep in original container, protect from moisture and light.

Diflucortolone valerate can interact with other medicines, especially those affecting corticosteroid metabolism or skin integrity.

Major Interactions (Avoid): - Systemic corticosteroids: additive systemic glucocorticoid effects. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may increase local drug levels. - Antifungal agents applied to the same area: risk of enhanced irritation.

Moderate Interactions (Monitor Closely): - Topical NSAIDs: may increase local irritation. - Photosensitizing agents (e.g., retinoids): heightened risk of phototoxicity. - Other topical immunosuppressants (e.g., tacrolimus): additive immunosuppression.